Sevoflurane and QTc Prolongation: An Interesting Observation, or a Clinically Significant Finding?
Scuderi
Phillip E
PE
D018685:Anesthetics, Inhalation / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D008738:Methyl Ethers / Q000009:adverse effects*; D026902:Potassium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D000077149:Sevoflurane; D051637:Shaker Superfamily of Potassium Channels / Q000187:drug effects / Q000502:physiology; D016171:Torsades de Pointes / Q000139:chemically induced
D018685:Anesthetics, Inhalation; D008738:Methyl Ethers; D026902:Potassium Channel Blockers; D051637:Shaker Superfamily of Potassium Channels; D000077149:Sevoflurane